Bill Directory

Drug Manufacturing Innovation Act of 2022

To direct the Secretary of Health and Human Services to conduct a pilot program under which the Secretary increases the conduct of unannounced inspections of foreign human drug establishments and evaluates the differences between inspections of domestic and foreign human drug establishments, including the impact of announcing inspections to persons who own or operate foreign human drug establishments in advance of an inspection.

Enhanced Access to Affordable Medicines Act of 2022

Pandemic Cessation Act

Accelerated Approval Integrity Act of 2022

Raising awareness of the impact of COVID-19 on bereaved children.

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to promulgate rules to update certain regulations relating to human cells, tissues, and cellular and tissue-based products, and for other purposes.

No Taxpayer Dollars for Communist China COVID Tests Act

SMALL GOVT Act of 2022

Patients Before Profits Act of 2022

Helping Experts Accelerate Rare Treatments Act of 2022

Healthcare Ownership Transparency Act

Supporting the designation of March 2022 as National Colorectal Cancer Awareness Month.

Expressing support for the designation of February 28, 2022, as "Rare Disease Day".

Right Drug Dose Now Act

Recognizing the 100th anniversary of the American College of Surgeons Committee on Trauma and the importance of preventing injury and saving more lives from injury around the globe.

Recognizing the extraordinary challenges faced by patients of color with rare diseases and the need to identify and promote evidenced-based solutions to alleviate the disproportionate burden of rare diseases on these communities and supporting the recognition of the last day in February as "Rare Disease Day".

No Pro-Abortion Task Force Act

Supporting women's cardiovascular health.

To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.